CSIMarket Company Name, Ticker, Competitors, else..
 
Alkermes Plc   (NASDAQ: ALKS)
 

Alkermes Plc's Suppliers Performance

ALKS's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ALKS Costs vs Sales of Suppliers Growth Alkermes Plc recorded an increase in cost of sales by 98.37 % year on year, sequentially cost of sales grew by 59.33 % in Q2.

• More on ALKS Suppliers



Alkermes Plc recorded increase in cost of sales by 98.37 % year on year, sequentially cost of sales grew by 59.33 % in Q2.

• More on ALKS Suppliers




Alkermes Plc's Comment on Supply Chain


The company manufactures clinical supplies of injectable extended-release and solid dosage form products at its Wilmington, Ohio facility. It also contracts with third-party manufacturers to formulate and produce certain clinical-use products in compliance with current Good Manufacturing Practice (cGMP) standards. The company holds multiple permits and licenses for manufacturing activities, including FDA Drug Establishment Registrations, DEA licenses, and authorizations from the Health Products Regulatory Authority in Ireland. Manufacturer Authorizations for the Athlone Facility were transferred to Novo following the sale of that facility in May 2024. Novo is identified as a supplier in company filings.

Alkermes Plc's Comment on Supply Chain


The company manufactures clinical supplies of injectable extended-release and solid dosage form products at its Wilmington, Ohio facility. It also contracts with third-party manufacturers to formulate and produce certain clinical-use products in compliance with current Good Manufacturing Practice (cGMP) standards. The company holds multiple permits and licenses for manufacturing activities, including FDA Drug Establishment Registrations, DEA licenses, and authorizations from the Health Products Regulatory Authority in Ireland. Manufacturer Authorizations for the Athlone Facility were transferred to Novo following the sale of that facility in May 2024. Novo is identified as a supplier in company filings.







ALKS's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Alkermes Plc 7,086.58 1,667.65 66.12 2,050
SUBTOTAL 0.00 0.00 0.00 -


Sources: Alkermes Plc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Alkermes Plc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.